In vivo and in vitro estrogenic and progestagenic actions of Tibolone

Biological Research

Volumn 38, Issue 2-3, 2005, Pages 245-258

  Sadarangani, Anil ^a   Salgado, Ana María ^a   Kato, Sumie ^a   Pinto, Mauricio ^a   Carvajal, Andrés ^a   Monso, Carolina ^a   Owen, Gareth I ^a   Vigil, Pilar ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Breast endometrium cancer; Estrogenic; HRT; Progestagenic and tibolone

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; PROGESTERONE; PROTEIN BCL XL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STAT5 PROTEIN; THROMBOPLASTIN; TIBOLONE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INCIDENCE; CANCER RISK; CELL CULTURE; CELL STRAIN MCF 7; CELL TYPE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENDOMETRIUM; ENDOMETRIUM CANCER; ENDOMETRIUM CELL; ESTROGEN ACTIVITY; FEMALE; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PATIENT MONITORING; PHENOTYPE; POSTMENOPAUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSVAGINAL ECHOGRAPHY; UPREGULATION; WESTERN BLOTTING;

MINK CELL FOCUS-FORMING VIRUS;

EID: 27544502469     PISSN: 07169760     EISSN: None     Source Type: Journal    
DOI: 10.4067/S0716-97602005000200014     Document Type: Article

References (37)

1. GAMBRELL RD (1982) The menopause: benefits and risks of estrogen-progestogen replacement therapy. Fertil Steril 37(4): 457-74
2. AHLBORG HG, JOHNELL O, TURNER CH (2003) Bone loss and bone size after menopause. Engl J Med 349(4): 327-34
3. BERAL V, BULL D, REEVES G; Million Women Study Collaborators. (2005) Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 365(9470): 1543-51
4. GOMPEL A, CHAOUAT M, Jacob D (2002) In vitro studies of tibolone in breast cells. Fertil Steril 78(2): 351-359
5. EDERVEEN AG, KLOOSTERBOER HJ (1999). Tibolone, a steroid with a tissue-specific hormonal profile, completely prevents ovariectomy-induced bone loss in sexually mature rats. J Bone Miner Res 14(11): 1963-1970
6. CASTELO-BRANCO C, VICENTE JJ, FIGUERAS F, SANJUÁN A, MARTÍNEZ de OSABA MJ, CASALS E, PONS F, BALASCH J, VANRELL JA (2000) Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 34(2): 161-8
7. TASKIN O, MUDERRISOGLU H, AKAR M, SIMSEK M, MENDILCIOGLU I, KURSUN S (2004) Comparison of the effects of tibolone and estrogen replacement therapy on echocardiographic basic cardiac functions in post-menopausal women: a randomized placebo controlled study. Maturitas 48(4): 354-9
8. VAN DE VEN J, DONKER GH, SPRONG M (2002) Effect of tibolone (Org OD14) and its metabolites on aromatase and estrone sulfatase activity in human breast adipose stromal cells and in MCF-7 and T47D breast cancer cells. J Steroid Biochem Mol Biol 81(3): 237-47
9. OWEN GI, ZELENT A (2000) Origins and evolutionary diversification of the nuclear receptor superfamily. Cell Mol Life Sci 57(5): 809-27
10. OMOTO Y, EGUCHI H, YAMAMOTO-YAMAGUCHI Y (2003) Estrogen receptor (ER) betal and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 22(32): 5011-20
11. YAMASHITA H, IWASE H, TOMOYAMA T (2003) Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells. Oncogene 20; 22(11): 1638-52
12. SOLBACH C, ROLLER M, AHR A (2002) Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer. Int J Cancer 1;101(4): 390-4
13. HANANHAN D, WEINBERG RA (2000) The hallmarks of cancer. Cell. 100(1): 57-70
14. KONINGSBERG W, KIRCHHOFER D. RIEDERER M (2001) The tissue factor: VIIa: clinical significance, structure function, relationships and its role in signaling and metastasis. Tromb and Haemost 86(5): 757-71
15. UENO T, TOI M, KOIKE M (2000) Tissue factor expression in breast tissue: its correlation with prognosis and plasma concentration. Br J. Cancer 83(2): 164-70
16. VRANA JA, STANG MT, Grande JP (1996) Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulated by carcinoma cell-derived members of the transforming growth factor beta family. Cancer Res 56(21): 5063-70
17. SHOJI M, HANCOCK W, ABE M (1998) Activation of coagulation and angiogeneis in cancer: Inmunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 52(2): 399-411
18. SORENSEN BB, RAO LV, TORNEHAVE D (2003) Anti-apoptotic effect of coagulation factor VIIa. Blood 102(5): 1708-15
19. SUBRAMANIAN T, CHINNNADURAI G (2003) Pro-apoptotic activity of transiently expressed BCL-2 occurs independent of BAX and BAK. J Cell Biochem 15; 89(6): 1102-14
20. ENGEL LW, YOUNG NA, TRALKA TS (1978). Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res 38(10): 3352-64
21. HORWITZ KB, COSTLOW ME, McGUIRE WL (1975) MCF-7; a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors. Steroids 26(6): 785-95.
22. NISHIDA M, KASAHARA K, KANEKO M (1985) Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Nippon Sanka Fujinka Gakkai Zasshi 37(7): 1103-1111
23. CHOMCZYNSKI P, SACCHI N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162(1): 156-159
24. SEEGER H, WALLWIENER D, MUECK AO (2003) The effect of progesterone and synthetic progestins on serum - and estradiol-stimulated proliferation of human breast cancer cells Horm Metab Res 35(2): 76-80
25. HATA H, KURAMOTO H (1992) Immunocytochemical determination of estrogen and progesterone receptors in human endometrial adenocarcinoma cells (Ishikawa cells). J Steroid Biochem Mol Biol 42(2): 201-210
26. KATO S, PINTO M, CARVAJAL A, ESPINOZA N, MONSO C, SADARANGANI A, VILLALÓN M, BROSENS JJ, WHITE JO, RICHER JK, HORWITZ KB, OWEN GI (2005) Progesterone increases Tissue Factor gene expression, procoagulant activity and invasion in the breast cancer cell line ZR-75-1. J Clin Endocrinol Metab 90(2): 1181-8
27. HUBER J, PALACIOS S, BERGLUND L (2002) Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG 109(8): 886-93
28. VOLKER W, CoOELINGH BENNINK HJ, HELMOND FA (2001) Effects of tibolone on the endometrium. Climacteric 4(3): 203-8
29. BERNING B, van KUIJK C, BENNINK HJ (2000) Absent correlation between vaginal bleeding and estradiol levels or endometrial morphology during tibolone use in early postmenopausal women. Maturitas 35(1): 81-8
30. BARKER S (2003) Anti-estrogens in the treatment of breast cancer: current status and future directions. Curr Opin Investig Drugs 4(6): 652-657
31. YAMASHITA H, IWASE H (2002). The role of Stat5 in estrogen receptor-positive breast cancer. Breast Cancer 9(4): 312-8
32. SILVA CM (2004) Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 3(48): 8017-8023
33. DAHM A, Van HYLCKAMA VLIEG A, BENDZ B (2003) Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 101(11): 4387-92
34. MEDINA R, ARANDA E, VERDUGO C, KATO S, OWEN GI 2003 The action of ovarian hormones in cardiovascular disease. Biol Res 36: 325-341
35. KATO S, PINTO M, CARVAJAL A, ESPINOZA N, MONSO C, BRAVO L, VILLALÓN M, CUELLO M, QUEST A.F., SUENAGA A, BROSENS JJ., OWEN GI. (2005). Tissue factor is regulated by epidermal growth factor in normal and malignant human endometrial epithelial cells. Thrombosis and Haemostasis., 94(2) 444-453
36. KLOOSTERBOER HJ (2001). Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 76(1-5): 231-238
37. GRAHAM JD, BAIN DL, RICHER JK, JACKSON TA, TUNG L, HORWITZ KB (2000). Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring? J Steroid Biochem Mol Biol 30; 74(5): 255-9.